Active Substances from the Micro-Immunotherapy Medicine 2LC1® Show In Vitro Anti-Cancer Properties - in Colon, Prostate, and Breast Cancer Models and Immune-Enhancing Capabilities in Human Macrophages

Sep 24, 2026

Uploaded by Rizky

Tumor-associated macrophages (TAMs) regulate cancer by shaping tumor growth, metastasis, and the immune microenvironment. Micro-immunotherapy (MI) medicines (MIM) deliver low and ultra-low doses of immune regulators, enabling targeting of TAM phenotype and function as adjuvant therapy across cancers. This study evaluates four 2LC1® capsules (2LC1-1, 2LC1-6, 2LC1-7, 2LC1-8) and ultra-low-dose SNA-MYC nucleic acid sequence in vitro in multiple cancer models and human monocyte-derived macrophages. Results show increased spheroid death and reduced spheroid volume in HCT-116 colon cancer, impaired clonogenic capacity in LNCaP and MCF-7 lines, and reduced C-MYC expression in human M2 macrophages, alongside increased CD86 and HLA-DR and altered chemokine secretion, with 2LC1-8 enhancing phagocytosis.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages25

Reading Time1 h 3 min

AccessFree to download

Abstract

Keywords

1. Introduction

2. Materials and Methods

3. Results

4. Discussion

5. Conclusions

Article Active Substances from the Micro-Immunotherapy Medicine 2LC1® Show In Vitro Anti-Cancer Properties in Colon, Prostate, and Breast Cancer Models and Immune-Enhancing Capabilities in Human Macrophages Camille Jacques 1, *, Irene Marchesi 2, Francesco Paolo Fiorentino 2, Flora Marchand 3, Mathias Chatelais 3 and Ilaria Floris 1 Academic Editor: Christiana Neophytou Received: 2 April 2025 Revised: 25 April 2025 Accepted: 28 April 2025 Published: 1 May 2025 Citation: Jacques, C.; Marchesi, I.; Fiorentino, F.P.; Marchand, F.; Chatelais, M.; Floris, I. Active Substances from the MicroImmunotherapy Medicine 2LC1® Show In Vitro Anti-Cancer Properties in Colon, Prostate, and Breast Cancer Models and Immune-Enhancing Capabilities inHuman Macrophages. Int. J. Mol. Sci. 2025, 26, 4300. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26094300](doi.org/10.3390/ijms26094300) [Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) . 1 Preclinical Research Department, Labo’life France, Pescalis-Les Magnys, 79320 Moncoutant-sur-Sevre, France; [ilaria.floris@labolife.com](ilaria.floris@labolife.com) 2 Kitos Biotech s.r.l.s., Porto Conte Ricerche, S.P. 55 Porto Conte-Capo Caccia, Km 8,400 Loc. Tramariglio, 07041 Alghero, Italy; [iremarchesi@gmail.com](iremarchesi@gmail.com) (I.M.); [fpfiorentino@gmail.com](fpfiorentino@gmail.com) (F.P.F.) 3 ProfileHIT, 7 Rue du Buisson, 44680 Sainte-Pazanne, France; flora.marchand@profile-hit.com (F.M.); [mathias.chatelais@profile-hit.com](mathias.chatelais@profile-hit.com) (M.C.) * Correspondence: [camille.jacques@labolife.com](camille.jacques@labolife.com) Abstract: Tumor-associated macrophages (TAMs) play a pivotal role in cancer regulation by influencing tumor growth, metastasis, and the immune microenvironment. By providing low doses and ultra-low doses (ULD) of immune regulators to the organism, micro-immunotherapy (MI) medicines (MIM) could be seen as valuable adjuvant drugs in the context of a wide range of pathological conditions, including cancers. Thus, these MIM could target TAMs, affecting their phenotype and activities. In this study, the antitumor and the immune-stimulatory effects of four capsules out of the ten composing the Labo’life’s MIM 2LC1® (2LC1-1, 2LC1-6, 2LC1-7, and 2LC1-8), as well as the specific nucleic acid (SNA® ) sequence SNA-MYC present at ULD in this medicine have been evaluated in vitro, in several cancer models, and in human monocyte-derived macrophages. Our results showed that the tested MI formulations increased the tumor cell death of spheroids from HCT-116 colon cancer cells, while reducing the spheroid volume. Moreover, the treatments impaired the clonogenic capabilities of two cancer cell lines from epithelial origin, the LNCaP prostate cancer and the MCF-7 breast cancer cells. Interestingly, ULD of the SNA-MYC shared similar anti-cancer capabilities in those models, and it led to a significant reduction in the expression of C-MYC when evaluated in a model of human M2 macrophages. In the same model, the MI formulations also increased the expression of CD86 and HLA-DR, two markers of M1 anti-tumor macrophages. In addition, the tested items modulated the secretion of a panel of chemokines related to macrophage activity and immune cell recruitment. Finally, our results showed that 2LC1-8 increased the phagocytosis capabilities of human monocyte-derived macrophages, thus possibly contributing to sustaining the immune functions of M1, which are crucial in the context of cancer. Even if more research is needed to uncover their exact mechanism of action, these results suggest that the tested capsules of 2LC1 as well as ULD of SNA-MYC display both anti

FAQs

What role do tumor-associated macrophages play in cancer regulation?

Tumor-associated macrophages influence tumor growth, metastasis, and the immune microenvironment, making them central to cancer regulation.

Which 2LC1® capsules and immune target sequence were tested in vitro?

Four 2LC1® capsules (2LC1-1, 2LC1-6, 2LC1-7, 2LC1-8) and the ultra-low-dose SNA-MYC nucleic acid sequence were evaluated in vitro.

What immune-related markers and functional changes were observed in macrophage models?

Ultra-low-dose treatments reduced C-MYC expression in human M2 macrophages, increased CD86 and HLA-DR expression, modulated chemokine secretion, and 2LC1-8 enhanced phagocytosis capacity.

Sep 24, 2026

Uploaded by Rizky